Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant

被引：28

作者：

Menozzi, Giulia ^{[1
]}

Fossa, Paola ^{[1
]}

Cichero, Elena ^{[1
]}

Spallarossa, Andrea ^{[1
]}

Ranise, Angelo ^{[1
]}

Mosti, Luisa ^{[1
]}

机构：

[1] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 43卷 / 12期

关键词：

1,5-Diarylpyrazoles; CB1; antagonists; Rimonabant analogues; Synthesis; Computational studies;

D O I：

10.1016/j.ejmech.2008.01.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Among cannabinoid type-1 (CB1) receptor antagonists, those developed around the 1,5-diarylpyrazole scaffold of rimonabant (Acomplia (TM)) are the most extensively investigated. In recent years, many SAR and QSAR reports on this topic have been published, focusing on the substitution and orientation of the N1 and C5 aryl functionalities and on the substituents at the 3-carboxamide position. In this context, the purpose of our study was to design and synthesize a set of 1-(2,4-dichlorophenyl)-5-arylpyrazoles strictly related to rimonabant, but with the hydrazide/amide group shifted from position 3 to position 4 of the pyrazole scaffold. The synthesized compounds were evaluated in vitro for their affinity on human CB1 and CB2 (cannabinoid type-2) receptors. Computational studies, performed both in the design step and after biological assays, contributed to rationalize the obtained results in terms of specific molecular interactions between antagonists and the human CB1 receptor. (C) 2008 Elsevier Masson SAS. All rights reserved.

引用

页码：2627 / 2638

页数：12

共 35 条

[1]

Adam G., 2001, World Patent, Patent No. [US 2005/0080087 A1, 20050080087, WO01/29011]

[2] Synthesis of novel 5-substituted pyrazole derivatives as cannabinoid antagonists [J].

Alekseeva, OO ;

Mahadevan, A ;

Wiley, JL ;

Martin, BR ;

Razdan, RK .

TETRAHEDRON LETTERS, 2005, 46 (12) :2159-2161

[3]

Barth F, 1999, CURR MED CHEM, V6, P745

[4]

BENAVIDES J, 2006, Patent No. 7105504

[5] Rimonabant: Just an Antiobesity drug? Current evidence on its pleiotropic effects [J].

Bifulco, Maurizio ;

Grimaldi, Claudia ;

Gazzerro, Patrizia ;

Pisanti, Simona ;

Santoro, Antonietta .

MOLECULAR PHARMACOLOGY, 2007, 71 (06) :1445-1456

[6] Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives:: A novel series of CB1 receptor antagonists [J].

Bostrom, Jonas ;

Berggren, Kristina ;

Elebring, Thomas ;

Greasley, Peter J. ;

Wilstermann, Michael .

BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (12) :4077-4084

[7] Rimonabant: The first therapeutically relevant cannabinoid antagonist [J].

Carai, MAM ;

Colombo, G ;

Gessa, GL .

LIFE SCIENCES, 2005, 77 (19) :2339-2350

[8]

Chemical Computing Group, MOE MOL OP ENV

[9] Synthesis and structure-activity relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1 (CB1) receptor ligands for potential use in molecular imaging [J].

Donohue, SR ;

Halldin, C ;

Pike, VW .

BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (11) :3712-3720

[10] Potent imidazole and triazole CB1 receptor antagonists related to SR141716 [J].

Dyck, B ;

Goodfellow, VS ;

Phillips, T ;

Grey, J ;

Haddach, M ;

Rowbottom, M ;

Naeve, GS ;

Brown, B ;

Saunders, J .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1151-1154

← 1 2 3 4 →